Degrasyn-like symmetrical compounds: Possible therapeutic agents for multiple myeloma (MM-I)
摘要:
A series of degrasyn-like symmetrical compounds have been designed, synthesized, and screened against B cell malignancy (multiple myeloma, mantle cell lymphoma) cell lines. The lead compounds T5165804 and CP2005 showed higher nanomolar potency against these tumor cells in comparison to degrasyn and inhibited Usp9x activity in vitro and in intact cells. These observations suggest that this new class of compounds holds promise as cancer therapeutic agents. (C) 2014 Published by Elsevier Ltd.
Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
申请人:Emory University
公开号:EP2364702A2
公开(公告)日:2011-09-14
A composition is provided which comprises one or more Kinase inhibitors for use for preventing or treating a pathogenic infection caused by a broad array of pathogens in a patient in need thereof.
Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof
申请人:Kalman Daniel
公开号:US20100249122A1
公开(公告)日:2010-09-30
The present invention provides compositions and methods of use thereof to prevent and/or treat pathogenic infection. In particular, the present invention provides the use of kinase inhibitors to inhibit kinases that involve in pathogen-host cell interactions that are associated with or cause pathogenic infections, therefore, to effectively prevent and/or treat pathogenic infections with far less likely to engender resistance as compared to conventional antibiotics and anti-viral drugs. The present invention further provides the use of kinase inhibitors for the treatment of acute pathogenic infections for a short period of time to avoid toxicities that may caused by long term use of these kinase inhibitors.
KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF
申请人:Kalman Daniel
公开号:US20120302565A1
公开(公告)日:2012-11-29
The present invention provides compositions and methods of use thereof to prevent and/or treat pathogenic infection. In particular, the present invention provides the use of kinase inhibitors to inhibit kinases that involve in pathogen-host cell interactions that are associated with or cause pathogenic infections, therefore, to effectively prevent and/or treat pathogenic infections with far less likely to engender resistance as compared to conventional antibiotics and anti-viral drugs. The present invention further provides the use of kinase inhibitors for the treatment of acute pathogenic infections for a short period of time to avoid toxicities that may caused by long term use of these kinase inhibitors.